Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person ceritinib-resistant ALK mutants don't bind ceritinib

Class:Id	FailedReaction:9700658
_displayName	ceritinib-resistant ALK mutants don't bind ceritinib
_doRelease	TRUE
_timestamp	2021-05-04 17:36:34
authored	[InstanceEdit:9724129] Rothfels, Karen, 2021-03-22
compartment	[Compartment:70101] cytosol [Compartment:876] plasma membrane
created	[InstanceEdit:9700663] Rothfels, Karen, 2020-09-16
disease	[Disease:1500689] cancer
edited	[InstanceEdit:9725664] Rothfels, Karen, 2021-03-30
entityFunctionalStatus	[EntityFunctionalStatus:9714049] loss_of_function of ceritinib-resistant ALK mutants [plasma membrane]
input	[DefinedSet:9700553] ceritinib-resistant ALK mutants [plasma membrane] [Homo sapiens] [ChemicalDrug:9699602] ceritinib [cytosol]
isChimeric	FALSE
literatureReference	[LiteratureReference:9713917] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer [LiteratureReference:9700350] The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer [LiteratureReference:9713886] Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor [LiteratureReference:9700357] Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma [LiteratureReference:9717267] TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors
modified	[InstanceEdit:9710922] Rothfels, Karen, 2021-01-05 [InstanceEdit:9715362] Rothfels, Karen, 2021-02-17 [InstanceEdit:9717355] Rothfels, Karen, 2021-03-08 [InstanceEdit:9724130] Rothfels, Karen, 2021-03-22 [InstanceEdit:9729590] Rothfels, Karen, 2021-04-30 [InstanceEdit:9729893] Rothfels, Karen, 2021-05-04 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	ceritinib-resistant ALK mutants don't bind ceritinib
normalReaction	[Reaction:9700662] Liganded-ALK dimer binds type I ALK-binding TKIs [Homo sapiens]
releaseDate	2021-06-09
reviewed	[InstanceEdit:9729891] Inghirami, Giorgio, 2021-05-04
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9700674] R-HSA-9700658.2
summation	[Summation:9714027] The following ALK mutants are resistant to inhibition by cer...
(hasEvent)	[Pathway:9717323] ceritinib-resistant ALK mutants [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by ceritinib-resistant ALK mutants don't bind ceritinib (9700658)